Home Business Bio Tech Circio and NeoRegen Advance Ge...

Circio and NeoRegen Advance Gene Therapy with New In Vivo RNA Delivery Technology

Bio Tech

Business Honor - Circio & NeoRegen Advance Gene Therapy with RNA Delivery Tech

Business Honor
01 July, 2025

Circio and NeoRegen’s collaboration advances gene therapy with innovative circRNA and advanced delivery technologies.

Circio Holding ASA and NeoRegen Biotech are one step closer to advancing their collaboration to transform gene therapy. The two firms have signed a second Material Transfer Agreement (MTA) representing the advancement of their collaboration to the in vivo preclinical stage. This follows on the heels of promising proof-of-concept (POC) data from their earlier in vitro experiments conducted under their initial MTA signed in 2023.

The partnership is aimed at resolving major challenges in the administration of nucleic acid-based drugs, in particular circular RNA (circRNA). Circio, the leader in circRNA expression systems, is known for its circVec platform, which has shown enormous potential to enhance both the stability and expression of viral and non-viral drugs. NeoRegen Biotech brings its intracellular delivery capability with its NICT (Neoregen Intra-Cellular delivery Technology) platform, which itself has been proven to perform better in cellular penetration and endosomal escape compared to conventional delivery methods.

The goal of the in vivo study is to demonstrate the therapeutic efficacy of circRNA vectors by combining circVec with NICT to transcend one of the greatest challenges in gene and cell therapy—delivery of nucleic acid drugs into cells in an efficient, targeted, and stable intracellular manner. The combination of these innovative technologies is anticipated to extend the limits of RNA therapeutics, providing better therapy for diverse genetic diseases. Dr. Jeongmin Seo, NeoRegen CEO, highlighted the significance of the shift into in vivo studies, saying, "This partnership has the potential to break through primary delivery hurdles and realize the full potential of gene and cell therapies." As the program moves forward, the two companies seek to choose certain disease targets for advanced development, pushing their combined R&D efforts toward clinical trials.